From Pioneer to the World's Leading Scientific Network

"Pioneers" was the headline when Science magazine covered the launch of the academic networking platform ResearchGATE exactly one year ago. In a very short time, a small group of pioneers in scientific communication, located at Harvard University and Hannover Medical School (Germany), has managed to create a worldwide community with more than 50,000 members from 196 countries.

In just twelve months, ResearchGATE has achieved its goal (called "ambitious" by Science magazine) of establishing itself as the world's leading social network for researchers focused on life sciences. Moreover, ResearchGATE offers far more than the usual networking features: Many different tools and applications greatly simplify scientific collaboration and research.

Within the platform, 1,100 issue-specific groups have been founded. Several research organizations and academic institutions cooperate with ResearchGATE, thereby contributing to the growing depth and reach of the platform. A new concept for sub-communities allows such organizations to create their own, closed "network within the network", ensuring confidentiality while giving members the opportunity for exchange with the global research community. Currently, this concept is carried out with the prestigious German Society for Virology (counting noble prize winner Harald zur Hausen into its ranks). Now, it will be made available to the entire scientific world.

By launching its semantic search engine for scientific literature and its automated matching processes, ResearchGATE has distanced typical Web 2.0 applications in terms of usability and member benefits. These tools enable researchers to find groups, papers, fellow researchers and everything else within and outside of ResearchGATE without having to read through dozens of irrelevant search results. The Similar Abstract Search Engine (SASE) allows users to upload entire abstracts and find thematically related papers within the platform and in external databases containing 30 million articles.

Moreover, individual users as well as groups of potential interest to the researcher are automatically suggested. File sharing, scheduling and voting tools add to the functionality of the platform.

Over the past twelve months, ResearchGATE's IT team has written more than 800,000 lines of code and installed 232 versions of ResearchGATE on its productive system. The feedback of members, the worldwide publicity and the constant requests from academic institutions seem to show that ResearchGATE is on the right path. Its value for members will continue to increase: Several cutting-edge tools and applications are scheduled to be released soon. Additional institutional cooperations will further enhance the quality of the network.

For further information, please visit:
http://www.researchgate.net

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...